神刊丨乳腺癌发病死亡生存筛查年报

发表时间:2022-10-10 10:02


从2011年开始,美国癌症学会隔年对美国女性乳腺癌统计数据进行更新,其中包括发病、死亡、生存和钼靶筛查。上次更新为2019年,本次原定于2021年更新,受到疫情的影响,推迟至2022年。


2022年10月3日,全球影响因子第一神刊、美国癌症学会《临床医师癌症杂志》在线发表美国癌症学会、埃默里大学、康奈尔大学威尔医学院的美国女性乳腺癌发病、死亡、生存和钼靶筛查统计数据更新,全文长达18页。此外,受到疫情的影响,神刊的影响因子虽然已从508.702跌至286.130,但是仍然比排名第二的英国《柳叶刀》高出83.399分。



过去40年的大部分时间,乳腺癌发病率都在上升;尤其2010~2019年,发病率每年增加0.5%,主要由于早期乳腺癌和激素受体阳性乳腺癌。


相比之下,乳腺癌死亡率自1989年达到峰值以来稳步下降,尽管近10年的下降速度(2011~2020年每年1.3%)低于前10年(2002~2011年每年1.9%)。


总体而言,1989~2020年死亡率下降43%,这意味着期间乳腺癌死亡病例减少了46万例。全部种族或民族人群女性死亡率都出现类似下降,除了美洲印第安人和阿拉斯加原住民死亡率保持稳定。


不过,虽然黑人女性与白人女性相比,乳腺癌发病率较低(10万分之127.8比133.7),但是乳腺癌死亡率高40%(2016~2020年10万分之27.6比19.7),而50岁以下成年女性乳腺癌死亡率高1倍(10万分之12.1比6.5)。


黑人女性与白人女性相比,乳腺癌各个分子亚型和分期(一期除外)5年相对生存率都较低:

  • 激素受体阳性HER2阴性乳腺癌:88%比96%

  • 激素受体阴性HER2阳性乳腺癌:78%比86%

  • 三期乳腺癌:64%比77%


因此,该研究结果表明,通过扩大联邦医疗补助覆盖范围,促进利益相关者、乳腺癌宣传组织与医疗卫生系统的合作关系,增加获得高质量筛查和治疗的机会,从而减少种族差异,可以加速降低乳腺癌死亡率的进展。



CA Cancer J Clin. 2022 Oct 3. IF: 286.130

Breast Cancer Statistics, 2022.

Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL.

American Cancer Society, Atlanta, Georgia, USA; Emory University, Atlanta, Georgia, USA; Weill Cornell Medicine, New York, New York, USA.

This article is the American Cancer Society's update on female breast cancer statistics in the United States, including population-based data on incidence, mortality, survival, and mammography screening. Breast cancer incidence rates have risen in most of the past four decades; during the most recent data years (2010-2019), the rate increased by 0.5% annually, largely driven by localized-stage and hormone receptor-positive disease. In contrast, breast cancer mortality rates have declined steadily since their peak in 1989, albeit at a slower pace in recent years (1.3% annually from 2011 to 2020) than in the previous decade (1.9% annually from 2002 to 2011). In total, the death rate dropped by 43% during 1989-2020, translating to 460,000 fewer breast cancer deaths during that time. The death rate declined similarly for women of all racial/ethnic groups except American Indians/Alaska Natives, among whom the rates were stable. However, despite a lower incidence rate in Black versus White women (127.8 vs. 133.7 per 100,000), the racial disparity in breast cancer mortality remained unwavering, with the death rate 40% higher in Black women overall (27.6 vs. 19.7 deaths per 100,000 in 2016-2020) and two-fold higher among adult women younger than 50 years (12.1 vs. 6.5 deaths per 100,000). Black women have the lowest 5-year relative survival of any racial/ethnic group for every molecular subtype and stage of disease (except stage I), with the largest Black-White gaps in absolute terms for hormone receptor-positive/human epidermal growth factor receptor 2-negative disease (88% vs. 96%), hormone receptor-negative/human epidermal growth factor receptor 2-positive disease (78% vs. 86%), and stage III disease (64% vs. 77%). Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high-quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.

KEYWORDS: breast neoplasms, epidemiology, health disparities, incidence, molecular subtype

PMID: 36190501

DOI: 10.3322/caac.21754



-end-


加入癌症早筛行业交流群,请关注早筛网公众号,后台回复“进群”



正在与早筛网同行的伙伴,期待与您携手为拯救生命而战!

正在与早筛网同行的伙伴,期待与您携手为拯救生命而战!

--

早筛网公众号
早筛医声公众号
地址:广州市黄埔区天泰路1号5A层/武汉市汉阳区龟北路1号汉阳造文化创意园6-4#

邮编:510000/430000

早筛网是聚焦于健康筛查的学术交流和产业服务平台,以专业的报道推动中国医疗从“以治病为中心”转变为“以人民健康为中心”,以“预防是最经济最有效的健康策略”为方针,普及“早筛查、早诊断、早治疗”理念和中医“治未病”理念,旨在让疾病诊于早期从而得以被治愈。
关于早筛网
联系我们